1. Home
  2. FRPH vs CUVL Comparison

FRPH vs CUVL Comparison

Compare FRPH & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FRP Holdings Inc.

FRPH

FRP Holdings Inc.

N/A

Current Price

$22.14

Market Cap

420.6M

Sector

Finance

ML Signal

N/A

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$7.80

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
FRPH
CUVL
Founded
1986
N/A
Country
United States
Australia
Employees
N/A
16
Industry
Real Estate
Miscellaneous
Sector
Finance
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
420.6M
374.2M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
FRPH
CUVL
Price
$22.14
$7.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
95.7K
6.5K
Earning Date
04-10-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$42,846,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.57
N/A
52 Week Low
$20.53
$6.20
52 Week High
$26.32
$8.20

Technical Indicators

Market Signals
Indicator
FRPH
CUVL
Relative Strength Index (RSI) 51.09 58.90
Support Level $21.92 $6.45
Resistance Level $24.57 N/A
Average True Range (ATR) 0.54 0.29
MACD 0.15 0.10
Stochastic Oscillator 66.09 66.66

Price Performance

Historical Comparison
FRPH
CUVL

About FRPH FRP Holdings Inc.

FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: